{"mainPropery":{"diseaseId":9596,"diseaseName":"Acquired amegakaryocytic thrombocytopenia","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/9596/acquired-amegakaryocytic-thrombocytopenia","synonyms":["Severe thrombocytopenia and selective, marked decrease or absence of megakaryocytes","AAT","Acquired pure megakaryocytic aplasia"],"synonyms-with-source":[{"name":"Severe thrombocytopenia and selective, marked decrease or absence of megakaryocytes"},{"name":"AAT"},{"name":"Acquired pure megakaryocytic aplasia"}],"identifiers":[]},"diseaseCategories":[],"organizations":[{"resourceID":248,"resourceName":"Platelet Disorder Support Association","abbreviation":"","address1":"8751 Brecksville Road","address2":"Suite 150","address3":"","address4":"","address5":"","city":"Cleveland","state":"OH","zip":"44141","country":"United States","phone":"440-746-9003","tty":"","tollFree":"87-PLATELET (1-877-528-3538)","fax":"844-270-1277","email":"pdsa@pdsa.org","url":"http://www.pdsa.org/","freeText":""}],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=(acquired%5BTitle%2FAbstract%5D+AND+amegakaryocytic%5BTitle%2FAbstract%5D+AND+thrombocytopenic%5BTitle%2FAbstract%5D+AND+purpura%5BTitle%2FAbstract%5D)+OR+(acquired%5BTitle%2FAbstract%5D+AND+pure%5BTitle%2FAbstract%5D+AND+megakaryocytic%5BTitle%2FAbstract%5D+AND+aplasia%5BTitle%2FAbstract%5D)' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Acquired amegakaryocytic thrombocytopenia. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='https://clinicaltrials.gov/ct2/results?term=Acquired+amegakaryocytic+thrombocytopenia&Search=Search' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Acquired amegakaryocytic thrombocytopenia. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":983,"resourceId":1678,"resourceName":"NHLBI - Thrombocytopenia","descriptionText":"The <a href='http://www.nhlbi.nih.gov/health/dci/Diseases/thcp/thcp_what.html ' target='_blank'>National Heart Lung and Blood Institute</a> (NHLBI) provides information on thrombocytopenia in general. The NHLBI was created to conduct research and distribute health information on diseases of the heart, blood vessels, lungs, and blood.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/MESH:C538172' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"}],"overviewQuestion":{"questionId":2083,"questionText":"What is acquired amegakaryocytic thrombocytopenia?<br />","answerText":"<strong>Acquired amegakaryocytic thrombocytopenia</strong> is a rare blood disorder that causes severe <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000586.htm\" target=\"_blank\">thrombocytopenia</a> with no other blood abnormalities. It is so named because the level of large bone marrow cells that produce <a href=\"https://www.nlm.nih.gov/medlineplus/plateletdisorders.html\" target=\"_blank\">platelets</a>, called megakaryocytes, are significantly lower or absent.[9867][9868] Signs and symptoms of the condition include prolonged bleeding; easy bruising; rash (pinpoint red spots called petechia); bleeding in the mouth and gums; and/or frequent nosebleeds.[9865][9866] There are many potential <a href=\"https://rarediseases.info.nih.gov/gard/9596/acquired-amegakaryocytic-thrombocytopenia/resources/10\" target=\"_blank\">causes</a> of the condition. Although standard treatment guidelines have not been established, various immunosuppressive treatment approaches have been utilized with success in affected people.[9867][9868]&nbsp;","dateModified":"2015-10-26T00:00:00"},"basicQuestions":[{"questionId":9588,"questionText":"What are the signs and symptoms of acquired amegakaryocytic thrombocytopenia?","answerText":"The signs and symptoms of acquired amegakaryocytic thrombocytopenia vary but may include:[9865][9866]\r\n<ul>\r\n    <li>Prolonged bleeding, even from minor cuts</li>\r\n    <li>Easy bruising</li>\r\n    <li>Rash (pinpoint red spots called petechia)</li>\r\n    <li>Bleeding in the mouth and gums</li>\r\n    <li>Frequent nosebleeds</li>\r\n</ul>\r\n<br />","dateModified":"2015-10-26T14:18:00","resourceClassificationName":"Symptoms","references":[{"referenceId":9865,"authors":"","articleTitle":"Thrombocytopenia","bookWebsiteJournalTitle":"National Heart, Lung, and Blood Institute","date":"September 2012","volume":"","pages":"","url":"http://www.nhlbi.nih.gov/health/health-topics/topics/thcp","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9866,"authors":"","articleTitle":"Thrombocytopenia","bookWebsiteJournalTitle":"MedlinePlus","date":"February 2014","volume":"","pages":"","url":"https://www.nlm.nih.gov/medlineplus/ency/article/000586.htm","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":2084,"questionText":"What causes acquired amegakaryocytic thrombocytopenia?","answerText":"There are many potential causes of acquired amegakaryocytic thrombocytopenia. For example, the condition can be associated with:[9867][9868]\r\n<ul>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/viralinfections.html\" target=\"_blank\">Viral</a> infections</li>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/bacterialinfections.html\" target=\"_blank\">Bacterial</a> infections</li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002324.htm\" target=\"_blank\">Chemotherapy</a> </li>\r\n    <li>Exposure to environmental toxins</li>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000816.htm\" target=\"_blank\">Autoimmune diseases</a> (i.e. <a href=\"https://rarediseases.info.nih.gov/gard/10253/lupus/resources/1\" target=\"_blank\">systemic lupus erythematosus</a>)</li>\r\n    <li>Drug sensitivities</li>\r\n    <li>Pregnancy</li>\r\n</ul>\r\n<br />\r\nIn some people, the condition is an early sign of a more severe progressive disease, such as <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000554.htm\" target=\"_blank\">aplastic anemia</a>, <a href=\"http://www.cancer.gov/cancertopics/pdq/treatment/myelodysplastic/patient/\" target=\"_blank\">myelodysplasia</a>, or <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/001299.htm\" target=\"_blank\">leukemia</a>.[9867]","dateModified":"2015-10-26T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":9867,"authors":"Brown GE, Babiker HM, Cantu CL, Yeager AM, Krishnadasan R.","articleTitle":"\"Almost bleeding to death\": the conundrum of acquired amegakaryocytic thrombocytopenia","bookWebsiteJournalTitle":"Case Rep Hematol. 2014","date":"2014","volume":"","pages":"","url":"","dateAccessed":"2015-10-26T00:00:00","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9868,"authors":"Patel M, Kalra A, Surapaneni R, Schwarting R, Devereux L","articleTitle":"Acquired amegakaryocytic thrombocytopenia in a patient with occupational chemical exposure","bookWebsiteJournalTitle":"Am J Ther","date":"January-February 2014","volume":"21(1)","pages":"e17-20","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":9589,"questionText":"How is acquired amegakaryocytic thrombocytopenia diagnosed?","answerText":"A diagnosis of acquired amegakaryocytic thrombocytopenia is often suspected based on the presence of characteristic <a href=\"https://rarediseases.info.nih.gov/gard/9596/acquired-amegakaryocytic-thrombocytopenia/resources/9\" target=\"_blank\">signs and symptoms</a>. Additional testing can then be ordered to confirm the diagnosis. This may include:[9865][9866]\r\n<ul>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003642.htm\" id=\"anch_28\" target=\"_blank\">Complete blood count</a> (CBC) </li>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003665.htm\" target=\"_blank\">Blood smear</a></li>\r\n    <li>Blood clotting studies (<a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003653.htm\" id=\"anch_29\" target=\"_blank\">PTT</a> and <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003652.htm\" target=\"_blank\">PT</a>) </li>\r\n    <li><a href=\"http://www.nhlbi.nih.gov/health/health-topics/topics/bmt/\" target=\"_blank\">Bone marrow tests</a> (i.e. a bone marrow aspiration and/or biopsy)</li>\r\n</ul>\r\n<br />\r\nOnce the diagnosis is confirmed, a healthcare provider will likely recommend other tests in an attempt to determine the underlying cause of the condition.","dateModified":"2015-10-26T14:56:00","resourceClassificationName":"Diagnosis","references":[{"referenceId":9865,"authors":"","articleTitle":"Thrombocytopenia","bookWebsiteJournalTitle":"National Heart, Lung, and Blood Institute","date":"September 2012","volume":"","pages":"","url":"http://www.nhlbi.nih.gov/health/health-topics/topics/thcp","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9866,"authors":"","articleTitle":"Thrombocytopenia","bookWebsiteJournalTitle":"MedlinePlus","date":"February 2014","volume":"","pages":"","url":"https://www.nlm.nih.gov/medlineplus/ency/article/000586.htm","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":2085,"questionText":"How might acquired amegakaryocytic thrombocytopenia be treated?","answerText":"Standard treatment guidelines have not been established for acquired amegakaryocytic thrombocytopenia. However, various immunosuppressive treatment approaches have been utilized in affected people. In several case reports, affected people were successfully treated with <a href=\"https://www.nlm.nih.gov/medlineplus/druginfo/meds/a601207.html\" target=\"_blank\">cyclosporine</a> either alone or in combination with other immunosuppressive medications (i.e. antithymocyte globulin). Other therapies for acquired amegakaryocytic thrombocytopenia have included <a href=\"https://www.nlm.nih.gov/medlineplus/druginfo/meds/a607038.html\" target=\"_blank\">rituximab</a>, <a href=\"https://www.nlm.nih.gov/medlineplus/druginfo/meds/a682599.html\" target=\"_blank\">danazol</a>, <a href=\"https://www.nlm.nih.gov/medlineplus/druginfo/meds/a682167.html\" target=\"_blank\">azathioprine</a>, and <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003009.htm\" target=\"_blank\">bone marrow transplant</a> with variable success.[9867]<br />\r\n<br />\r\nTo determine the best treatment for you or a family member, please speak with a healthcare provider.","dateModified":"2015-10-26T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":9867,"authors":"Brown GE, Babiker HM, Cantu CL, Yeager AM, Krishnadasan R.","articleTitle":"\"Almost bleeding to death\": the conundrum of acquired amegakaryocytic thrombocytopenia","bookWebsiteJournalTitle":"Case Rep Hematol. 2014","date":"2014","volume":"","pages":"","url":"","dateAccessed":"2015-10-26T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":2086,"questionText":"What is the&nbsp;long-term outlook for&nbsp;people with acquired amegakaryocytic thrombocytopenia?","answerText":"The long-term outlook (prognosis) for people with acquired amegakaryocytic thrombocytopenia varies based on the underlying cause. Some people respond well to treatment and long-term <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=45867\" target=\"_blank\">remissions</a> have been documented in several case reports.[9867] In others, the condition progresses rapidly to <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000554.htm\" target=\"_blank\">aplastic anemia</a> or <a href=\"http://www.cancer.gov/cancertopics/pdq/treatment/myelodysplastic/patient/\" target=\"_blank\">myelodysplasia</a>.[1277] There are currently no good predictors to aid in assessing the likelihood of response to therapy or overall prognosis.[1278]","dateModified":"2015-10-26T00:00:00","resourceClassificationName":"Prognosis","references":[{"referenceId":1277,"authors":"Bulcahndani D et al.,","articleTitle":"Acquired pure megakaryocytic aplasia: Report of a single case treated with Mycophenolate Mofetil","bookWebsiteJournalTitle":"American Journal of Hematology","date":"2007"},{"referenceId":1278,"authors":"Felderbauer P et al.,","articleTitle":"Case Report: Acquired pure megakaryocytic aplasia: a seoarate haematological disease entity or a syndrome with multiple causes?","bookWebsiteJournalTitle":"Eur J Haematol","date":"2004"},{"referenceId":9867,"authors":"Brown GE, Babiker HM, Cantu CL, Yeager AM, Krishnadasan R.","articleTitle":"\"Almost bleeding to death\": the conundrum of acquired amegakaryocytic thrombocytopenia","bookWebsiteJournalTitle":"Case Rep Hematol. 2014","date":"2014","volume":"","pages":"","url":"","dateAccessed":"2015-10-26T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[],"gardCases":[{"caseId":23918,"abbreviatedInquiry":"I have acquired amegakaryocytic thrombocytopenia. Can you help me find more information on this disease, its treatment, and its long-term prognosis?","caseQuestions":[{"questionId":2083,"questionText":"What is acquired amegakaryocytic thrombocytopenia?<br />","answerText":"<strong>Acquired amegakaryocytic thrombocytopenia</strong> is a rare blood disorder that causes severe <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000586.htm\" target=\"_blank\">thrombocytopenia</a> with no other blood abnormalities. It is so named because the level of large bone marrow cells that produce <a href=\"https://www.nlm.nih.gov/medlineplus/plateletdisorders.html\" target=\"_blank\">platelets</a>, called megakaryocytes, are significantly lower or absent.[9867][9868] Signs and symptoms of the condition include prolonged bleeding; easy bruising; rash (pinpoint red spots called petechia); bleeding in the mouth and gums; and/or frequent nosebleeds.[9865][9866] There are many potential <a href=\"https://rarediseases.info.nih.gov/gard/9596/acquired-amegakaryocytic-thrombocytopenia/resources/10\" target=\"_blank\">causes</a> of the condition. Although standard treatment guidelines have not been established, various immunosuppressive treatment approaches have been utilized with success in affected people.[9867][9868]&nbsp;","dateModified":"2015-10-26T00:00:00","references":[{"referenceId":9865,"authors":"","articleTitle":"Thrombocytopenia","bookWebsiteJournalTitle":"National Heart, Lung, and Blood Institute","date":"September 2012","volume":"","pages":"","url":"http://www.nhlbi.nih.gov/health/health-topics/topics/thcp","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9866,"authors":"","articleTitle":"Thrombocytopenia","bookWebsiteJournalTitle":"MedlinePlus","date":"February 2014","volume":"","pages":"","url":"https://www.nlm.nih.gov/medlineplus/ency/article/000586.htm","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9867,"authors":"Brown GE, Babiker HM, Cantu CL, Yeager AM, Krishnadasan R.","articleTitle":"\"Almost bleeding to death\": the conundrum of acquired amegakaryocytic thrombocytopenia","bookWebsiteJournalTitle":"Case Rep Hematol. 2014","date":"2014","volume":"","pages":"","url":"","dateAccessed":"2015-10-26T00:00:00","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9868,"authors":"Patel M, Kalra A, Surapaneni R, Schwarting R, Devereux L","articleTitle":"Acquired amegakaryocytic thrombocytopenia in a patient with occupational chemical exposure","bookWebsiteJournalTitle":"Am J Ther","date":"January-February 2014","volume":"21(1)","pages":"e17-20","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":2084,"questionText":"What causes acquired amegakaryocytic thrombocytopenia?","answerText":"There are many potential causes of acquired amegakaryocytic thrombocytopenia. For example, the condition can be associated with:[9867][9868]\r\n<ul>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/viralinfections.html\" target=\"_blank\">Viral</a> infections</li>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/bacterialinfections.html\" target=\"_blank\">Bacterial</a> infections</li>\r\n    <li><a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002324.htm\" target=\"_blank\">Chemotherapy</a> </li>\r\n    <li>Exposure to environmental toxins</li>\r\n    <li><a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/000816.htm\" target=\"_blank\">Autoimmune diseases</a> (i.e. <a href=\"https://rarediseases.info.nih.gov/gard/10253/lupus/resources/1\" target=\"_blank\">systemic lupus erythematosus</a>)</li>\r\n    <li>Drug sensitivities</li>\r\n    <li>Pregnancy</li>\r\n</ul>\r\n<br />\r\nIn some people, the condition is an early sign of a more severe progressive disease, such as <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000554.htm\" target=\"_blank\">aplastic anemia</a>, <a href=\"http://www.cancer.gov/cancertopics/pdq/treatment/myelodysplastic/patient/\" target=\"_blank\">myelodysplasia</a>, or <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/001299.htm\" target=\"_blank\">leukemia</a>.[9867]","dateModified":"2015-10-26T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":9867,"authors":"Brown GE, Babiker HM, Cantu CL, Yeager AM, Krishnadasan R.","articleTitle":"\"Almost bleeding to death\": the conundrum of acquired amegakaryocytic thrombocytopenia","bookWebsiteJournalTitle":"Case Rep Hematol. 2014","date":"2014","volume":"","pages":"","url":"","dateAccessed":"2015-10-26T00:00:00","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":9868,"authors":"Patel M, Kalra A, Surapaneni R, Schwarting R, Devereux L","articleTitle":"Acquired amegakaryocytic thrombocytopenia in a patient with occupational chemical exposure","bookWebsiteJournalTitle":"Am J Ther","date":"January-February 2014","volume":"21(1)","pages":"e17-20","url":"","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":2085,"questionText":"How might acquired amegakaryocytic thrombocytopenia be treated?","answerText":"Standard treatment guidelines have not been established for acquired amegakaryocytic thrombocytopenia. However, various immunosuppressive treatment approaches have been utilized in affected people. In several case reports, affected people were successfully treated with <a href=\"https://www.nlm.nih.gov/medlineplus/druginfo/meds/a601207.html\" target=\"_blank\">cyclosporine</a> either alone or in combination with other immunosuppressive medications (i.e. antithymocyte globulin). Other therapies for acquired amegakaryocytic thrombocytopenia have included <a href=\"https://www.nlm.nih.gov/medlineplus/druginfo/meds/a607038.html\" target=\"_blank\">rituximab</a>, <a href=\"https://www.nlm.nih.gov/medlineplus/druginfo/meds/a682599.html\" target=\"_blank\">danazol</a>, <a href=\"https://www.nlm.nih.gov/medlineplus/druginfo/meds/a682167.html\" target=\"_blank\">azathioprine</a>, and <a href=\"https://www.nlm.nih.gov/medlineplus/ency/article/003009.htm\" target=\"_blank\">bone marrow transplant</a> with variable success.[9867]<br />\r\n<br />\r\nTo determine the best treatment for you or a family member, please speak with a healthcare provider.","dateModified":"2015-10-26T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":9867,"authors":"Brown GE, Babiker HM, Cantu CL, Yeager AM, Krishnadasan R.","articleTitle":"\"Almost bleeding to death\": the conundrum of acquired amegakaryocytic thrombocytopenia","bookWebsiteJournalTitle":"Case Rep Hematol. 2014","date":"2014","volume":"","pages":"","url":"","dateAccessed":"2015-10-26T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":2086,"questionText":"What is the&nbsp;long-term outlook for&nbsp;people with acquired amegakaryocytic thrombocytopenia?","answerText":"The long-term outlook (prognosis) for people with acquired amegakaryocytic thrombocytopenia varies based on the underlying cause. Some people respond well to treatment and long-term <a href=\"http://www.cancer.gov/publications/dictionaries/cancer-terms?CdrID=45867\" target=\"_blank\">remissions</a> have been documented in several case reports.[9867] In others, the condition progresses rapidly to <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/000554.htm\" target=\"_blank\">aplastic anemia</a> or <a href=\"http://www.cancer.gov/cancertopics/pdq/treatment/myelodysplastic/patient/\" target=\"_blank\">myelodysplasia</a>.[1277] There are currently no good predictors to aid in assessing the likelihood of response to therapy or overall prognosis.[1278]","dateModified":"2015-10-26T00:00:00","resourceClassificationName":"Prognosis","references":[{"referenceId":1277,"authors":"Bulcahndani D et al.,","articleTitle":"Acquired pure megakaryocytic aplasia: Report of a single case treated with Mycophenolate Mofetil","bookWebsiteJournalTitle":"American Journal of Hematology","date":"2007"},{"referenceId":1278,"authors":"Felderbauer P et al.,","articleTitle":"Case Report: Acquired pure megakaryocytic aplasia: a seoarate haematological disease entity or a syndrome with multiple causes?","bookWebsiteJournalTitle":"Eur J Haematol","date":"2004"},{"referenceId":9867,"authors":"Brown GE, Babiker HM, Cantu CL, Yeager AM, Krishnadasan R.","articleTitle":"\"Almost bleeding to death\": the conundrum of acquired amegakaryocytic thrombocytopenia","bookWebsiteJournalTitle":"Case Rep Hematol. 2014","date":"2014","volume":"","pages":"","url":"","dateAccessed":"2015-10-26T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[],"EncodedName":"Acquired_amegakaryocytic_thrombocytopenia"}